These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26444860)

  • 21. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
    Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
    Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis.
    Parra ER; Teodoro WR; de Morais J; Katayama ML; de Souza R; Yoshinari NH; Capelozzi VL
    Eur J Clin Invest; 2010 Feb; 40(2):110-20. PubMed ID: 19968698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis.
    Maurer B; Distler A; Suliman YA; Gay RE; Michel BA; Gay S; Distler JH; Distler O
    Ann Rheum Dis; 2014 Oct; 73(10):1880-7. PubMed ID: 23918036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
    Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
    Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis.
    Gilbane AJ; Derrett-Smith E; Trinder SL; Good RB; Pearce A; Denton CP; Holmes AM
    Am J Respir Crit Care Med; 2015 Mar; 191(6):665-77. PubMed ID: 25606692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.
    Hoyles RK; Khan K; Shiwen X; Howat SL; Lindahl GE; Leoni P; du Bois RM; Wells AU; Black CM; Abraham DJ; Denton CP
    Arthritis Rheum; 2008 Apr; 58(4):1175-88. PubMed ID: 18383385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma.
    Zhou X; Tan FK; Reveille JD; Wallis D; Milewicz DM; Ahn C; Wang A; Arnett FC
    Arthritis Rheum; 2002 Nov; 46(11):2990-9. PubMed ID: 12428242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.
    Wei J; Ghosh AK; Chu H; Fang F; Hinchcliff ME; Wang J; Marangoni RG; Varga J
    Arthritis Rheumatol; 2015 May; 67(5):1323-34. PubMed ID: 25707573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
    Maurer B; Stanczyk J; Jüngel A; Akhmetshina A; Trenkmann M; Brock M; Kowal-Bielecka O; Gay RE; Michel BA; Distler JH; Gay S; Distler O
    Arthritis Rheum; 2010 Jun; 62(6):1733-43. PubMed ID: 20201077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis.
    Sugiura Y; Banno S; Matsumoto Y; Niimi T; Yoshinouchi T; Hayami Y; Naniwa T; Ueda R
    J Rheumatol; 2003 Jul; 30(7):1520-3. PubMed ID: 12858451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models of scleroderma: fresh insights.
    Artlett CM
    Curr Opin Rheumatol; 2010 Nov; 22(6):677-82. PubMed ID: 20720495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
    Thachil J
    Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
    Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma.
    Głodkowska-Mrówka E; Górska E; Ciurzyński M; Stelmaszczyk-Emmel A; Bienias P; Irzyk K; Siwicka M; Lipińska A; Ciepiela O; Pruszczyk P; Demkow U
    Respir Physiol Neurobiol; 2015 Apr; 209():69-75. PubMed ID: 25447676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.